Beydoun Hind A, Stadtmauer Laurel, Zhao Yueqin, Russell Helena, Matson David O, Oehninger Sergio
Graduate Program in Public Health, Eastern Virginia Medical School, 1123 Lewis Hall, 700 W. Olney Road, Norfolk, VA 23501-1980, USA.
J Womens Health (Larchmt). 2009 May;18(5):717-23. doi: 10.1089/jwh.2008.1149.
To examine the effect of polycystic ovary syndrome (PCOS), a marker of the metabolic syndrome, on selected indicators of in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) treatment success.
A retrospective cohort study was conducted using existing data on 69 IVF/ICSI treatment cycles undergone by PCOS women and a caliper-matched sample of 69 IVF/ICSI treatment cycles undergone by non-PCOS women over a 7-year period at a major fertility treatment center. Matching criteria were age and date at IVF/ICSI treatment initiation. Process and outcome measures were used to define successful IVF/ICSI treatment. Statistical significance was determined at an alpha level of 0.05.
The total number of oocytes and the number of immature oocytes retrieved in the process of an IVF/ICSI cycle were significantly higher in the context of PCOS. No significant differences were observed among PCOS and non-PCOS groups on various IVF/ICSI cycle outcomes, including high-grade embryo, pregnancy achievement, miscarriage, and live birth status.
Although IVF/ICSI yields more oocytes in the context of PCOS, IVF/ICSI outcomes do not differ significantly by PCOS status. Prospective cohort studies are needed to examine short-term and long-term health effects of PCOS in the context of IVF/ICSI.
研究多囊卵巢综合征(PCOS)这一代谢综合征标志物对体外受精(IVF)或卵胞浆内单精子注射(ICSI)治疗成功率相关指标的影响。
在一家大型生育治疗中心,采用回顾性队列研究,利用7年间PCOS女性接受的69个IVF/ICSI治疗周期的现有数据,以及年龄和IVF/ICSI治疗开始日期匹配的69个非PCOS女性IVF/ICSI治疗周期的样本。匹配标准为IVF/ICSI治疗开始时的年龄和日期。采用过程和结果指标来定义IVF/ICSI治疗成功。显著性水平设定为0.05。
在PCOS情况下,IVF/ICSI周期中获取的卵母细胞总数和未成熟卵母细胞数显著更高。在包括优质胚胎、妊娠成功、流产和活产状态等各种IVF/ICSI周期结果方面,PCOS组和非PCOS组之间未观察到显著差异。
尽管在PCOS情况下IVF/ICSI能获得更多卵母细胞,但IVF/ICSI的结果在PCOS状态下并无显著差异。需要进行前瞻性队列研究以检查PCOS在IVF/ICSI背景下的短期和长期健康影响。